This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Destiny Pharma Management

Management criteria checks 3/4

Destiny Pharma's CEO is Chris Tovey, appointed in Sep 2023, has a tenure of less than a year. total yearly compensation is £123.00K, comprised of 89.4% salary and 10.6% bonuses, including company stock and options. directly owns 0.042% of the company’s shares, worth €1.40K. The average tenure of the management team and the board of directors is 3.4 years and 6.3 years respectively.

Key information

Chris Tovey

Chief executive officer

UK£123.0k

Total compensation

CEO salary percentage89.4%
CEO tenureless than a year
CEO ownership0.04%
Management average tenure3.4yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Tovey's remuneration changed compared to Destiny Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023UK£123kUK£110k

-UK£6m

Compensation vs Market: Chris's total compensation ($USD157.25K) is below average for companies of similar size in the German market ($USD531.21K).

Compensation vs Earnings: Insufficient data to compare Chris's compensation with company performance.


CEO

Chris Tovey (59 yo)

less than a year

Tenure

UK£123,000

Compensation

Mr. Christopher John Tovey, also known as Chris, BSc, serves as Chief Executive Officer & Director of Destiny Pharma plc since September 1, 2023. He had been the Chief Operating Officer at GW Pharmaceutica...


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Tovey
CEO & Directorless than a yearUK£123.00k0.042%
€ 1.9k
William Love
Founder27.6yrsUK£250.00k6.8%
€ 309.2k
Shaun Claydon
CFO, Company Secretary & Director5.8yrsUK£270.00k0.025%
€ 1.2k
Debra Barker
Interim CMO & Senior Independent Directorless than a yearUK£213.00k0.092%
€ 4.2k

3.4yrs

Average Tenure

60.5yo

Average Age

Experienced Management: D89's management team is considered experienced (3.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Tovey
CEO & Directorless than a yearUK£123.00k0.042%
€ 1.9k
William Love
Founderno dataUK£250.00k6.8%
€ 309.2k
Shaun Claydon
CFO, Company Secretary & Director5.8yrsUK£270.00k0.025%
€ 1.2k
Debra Barker
Interim CMO & Senior Independent Director4.6yrsUK£213.00k0.092%
€ 4.2k
Anthony Nigel Rudd
Independent Chairman8yrsUK£34.00k3.93%
€ 178.7k
Richard Proctor
Member of Scientific Advisory Board6.3yrsno datano data
Nigel Brooksby
Non-Executive Director2.2yrsUK£41.00k0.36%
€ 16.6k
Vance Fowler
Member of Scientific Advisory Board6.3yrsno datano data
David Roblin
Chair of the Scientific Advisory Board6.3yrsUK£10.66kno data
Leonard Mermel
Member of Scientific Advisory Board6.3yrsno datano data
Glenn J. Whitman
Member of Scientific Advisory Board6.3yrsno datano data
E Dellinger
Member of Scientific Advisory Boardno datano datano data

6.3yrs

Average Tenure

62yo

Average Age

Experienced Board: D89's board of directors are considered experienced (6.3 years average tenure).